"We can now conclude that CAR-T cells can actually cure patients" – Carl June, pioneering CAR-T scientist. Excerpts from the Endpoints article: "A decade after the first-ever patients were infused
In Forbes' 5 Biggest Biotech Trends for 2022, top of the list is personalised medicine – of which CAR-T therapy is an outstanding example of. CAR-T therapy harnesses the power
Carina Biotech has entered a license agreement with Bayerische Patentallianz (BayPAT) to the CXCR6-transduced CAR-T cell technology developed at the University Hospital of Ludwig-Maximillian University of Munich (LMU). The agreement
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer in late
Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and management and attracted new institutional and impact investors including a cornerstone
Carina Biotech has entered a collaboration agreement with Melbourne biotech AdAlta to develop precision engineered, i-body enabled CAR-T therapies that provide new hope for patients with cancer. To learn more, watch
We are very pleased to welcome to our corporate team Jade Foeng, researcher & PhD student in Professor Shaun McColl's lab at University of Adelaide. Jade, a researcher with Carina for 3+
Carina Biotech's four-member Medical Advisory Board will advise us as we prepare to take our LGR5-targeted CAR-T cell for advanced colorectal cancer into the clinic over the next 12-18 months.
Emma Thompson is a PhD candidate in Professor Claudine Bonder's Vascular Biology & Cell Trafficking Laboratory at UniSA's Centre for Cancer Biology. Emma's research is focused on testing Carina Biotech's LGR5-targeting CAR-T
Story by Hayden Smith, featured in The Weekend Australian, 5 June 2021 Battling blood cancer in my 20s, I put my faith in a clinical trial for a promising new
